Insulin in Dosage Market Size Value in the Netherlands

The insulin dosage market in the Netherlands has experienced fluctuations over the past decade, with notable year-on-year variations. From 2012 to 2014, the market had a mixed performance, with periods of both growth and decline. A significant growth occurred in 2015 with a 17.41% increase, followed by a slight decrease and then a period of mild variations, ending 2020 on a notable low. Recent years reflected some recovery, with 2021 exhibiting a 14.15% increase, only to decline again in 2022. The CAGR over the last five years showed a general declining trend at -0.74%.

• The year-on-year change from 2021 to 2020 was positive at 14.15%, while from 2022 to 2021, it turned negative at -9.46%.
• The average annual variation (CAGR) over the past five years stands at -0.74%, indicating an overall decline.

Looking ahead, the market is expected to experience moderate changes. Key trends to watch for include advancements in insulin delivery methods, the impact of pricing regulations, and the integration of digital health solutions to improve diabetes management outcomes.